Nutra Pharma Corp. (OTCMKTS:NPHC) Herpes, Arthritis, Multiple Sclerosis

Nutra Pharma Corp. (OTCMKTS:NPHC) Herpes, Arthritis, Multiple Sclerosis

Nutra Pharma Corp. (OTCMKTS:NPHC) Herpes, Arthritis, Multiple Sclerosis

Nutra Pharma, through its subsidiary ReceptoPharm, has a pipeline of biopharmaceutical products under development. These research and development pipeline products consist of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis, HIV/AIDS, adrenomyeloneuropathy, herpes, rheumatoid arthritis and pain.

ReceptoPharm conducts research into a number of products with applications for neurological, immunological and viral conditions. The principal therapeutic target is associated with a group of nerve receptors comprising the nicotinic acetylcholine receptors, nAchRs, known for their involvement in smoking and addiction. Like nicotine, ReceptoPharm drugs can attach to the nAchR and prevent its’ activation or block viruses, like the rabies virus, from using it as an entry point into the cell. The nAchR is acknowledged to be a major receptor whose involvement in AIDS-dementia, Rabies, MG, Pain, and even Alzheimer’s disease isolates it as a prime drug target.

ReceptoPharm has deliberately sought to identify specific nAchR-interacting proteins as potential therapeutics. Unlike nicotine, ReceptoPharm’s principal products are not toxic or habit forming; additionally nicotine has no antiviral properties. Prior clinical experience demonstrates no adverse effects associated with administration of the products to animals or humans over long periods of time. The unexpected inhibition of the human immunodeficiency virus (HIV) by these types of drugs is a major step forward in the search for novel entities to fight HIV and AIDS and may lead to new therapies for other viral diseases.

R&D Pipeline

ReceptoPharm’s research and development pipeline consists of several novel therapies in various stages of development to prevent and/or treat Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN), Herpes, Rheumatoid Arthritis (RA) and Pain.

Planning
In Progress
Completed

Abbreviations
Preclinical (PC), Phase 1 (P-I), Phase 2 (P-II), Phase 3 (P-III)

RPI-78M

Indication
PC
P-I
P-II
P-III
Herpes Simplex Infections 1 & 2

RPI-MN

Indication
PC
P-I
P-II
P-III
Human Immunodeficiency Virus
Amyotrophic Lateral Sclerosis
Herpes Simplex Keratitis

RPI-78

Indication
PC
P-I
P-II
P-III

Cobroxin

Indication
Regulatory Status
Chronic Pain (OTC)
Marketing

 

Cobroxin for Chronic Pain
Cobroxin is the first over-the-counter pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis. For more information, visit http://www.Cobroxin.com.

Nyloxin

Indication
Regulatory Status
Chronic Pain Marketing

 

Nyloxin // Chronic Pain Relief
Nyloxin is an over-the-counter (OTC) pain reliever for the treatmentment of moderate to severe chronic pain. It is available as both an oral spray and as a topical gel. Nyloxin is specifically formulated to treat back pain, neck pain, headaches, joint pain, migraines, arthritis pain, pain from repetitive stress and neuralgia. For more information, visit http://www.Nyloxin.com.

Save

The following two tabs change content below.
Shayne Heffernan Funds Manager at HEFFX holds a Ph.D. in Economics and brings with him over 25 years of trading experience in Asia and hands on experience in Venture Capital, he has been involved in several start ups that have seen market capitalization over $500m and 1 that reach a peak market cap of $15b. He has managed and overseen start ups in Mining, Shipping, Technology and Financial Services.

You must be logged in to post comments :  
CONNECT WITH